PERK: a novel therapeutic target for neurodegenerative diseases? by Tao Ma & Eric Klann
Ma and Klann Alzheimer's Research & Therapy 2014, 6:30
http://alzres.com/content/6/3/30COMMENTARYPERK: a novel therapeutic target for
neurodegenerative diseases?
Tao Ma* and Eric KlannAbstract
Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative
diseases such as Alzheimer’s disease, Parkinson’s disease, and prion disease. Multiple lines of evidence have
emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase
RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published
study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease
phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting
PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative
diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.Introduction
Diseases such as Alzheimer’s disease (AD), Huntington’s
disease (HD), Parkinson’s disease (PD), and prion disease
usually are classified as neurodegenerative diseases that
represent a heterogeneous group of disorders character-
ized by progressive structural or functional neuronal loss
or both. Neurodegenerative diseases present great chal-
lenges for human public health because of the preva-
lence of the diseases, the severity of clinical symptoms
(usually lethal in the end), and the lack of effective treat-
ments. Great efforts have been made to try to under-
stand the etiology of neurodegenerative diseases. At the
subcellular and molecular levels, these diseases appear
to share many key similarities, which are potential
mechanisms underlying the pathophysiology and thus
are appealing as therapeutic targets. In a recently pub-
lished study by Moreno and colleagues [1], oral treat-
ment of a newly characterized and specific inhibitor
of the endoplasmic reticulum-localized kinase PERK
(protein kinase RNA-like endoplasmic reticulum kinase),
termed GSK2606414 [2], was demonstrated to rescue
clinical symptoms as well as brain pathology in a mouse
model of prion disease. Together with other recent rele-
vant studies, these findings have identified a potential* Correspondence: tm99@nyu.edu
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809, New York, NY 10003, USA
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2014novel therapeutic avenue for drug development to treat
neurodegenerative diseases.
PERK activation during stress response: protective
or detrimental?
A common feature among neurodegenerative diseases is
the accumulation of misfolded proteins, which consti-
tutes significant cellular stress that triggers the activation
of multiple signaling cascades and the unfolded protein
response (UPR). The UPR is mediated through three key
effectors: inositol-requiring enzyme 1, activating tran-
scription factor 6, and PERK [3]. As a crucial component
of the UPR, PERK activation results in phosphorylation
and inhibition of eukaryotic initiation factor 2α (eIF2α),
a translational factor that controls the initiation step of
protein synthesis which has been implicated in long-
term synaptic plasticity and memory formation [4]. As a
result of increased phosphorylation of eIF2α, global pro-
tein synthesis would be inhibited as a component of the
cellular stress response [5]. Short-term reduction of
general protein synthesis in response to cellular stress
typically is considered to be protective because it allows
cells to conserve energy resources while enhancing the
gene-specific translation of stress-related mRNAs,
thereby reconfiguring gene expression to cope with the
cellular stress [6]. In contrast, during severe and pro-
longed forms of cellular stress that are associated with
pathological conditions such as are found in neurode-
generative diseases, PERK activation is protracted suchl Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
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periods of time, leading to a long-lasting repression of
mRNA translation. An enhanced and prolonged increase
in eIF2α phosphorylation inevitably would be detrimen-
tal for cognitive function because intact mechanisms are
necessary to trigger de novo protein synthesis which are
required for long-lasting neuronal plasticity and memory
consolidation [7,8]. In short, a balanced UPR/PERK/
eIF2α pathway is critical for maintaining cellular homeo-
stasis during stress conditions.
PERK suppression as a strategy for
neurodegenerative diseases: promises and
caveats
In the study by Moreno and colleagues, prion-infected
mice were orally treated with GSK2606414 either before
or after the occurrence of clinical features of prion
disease, and remarkably the treatments successfully pre-
vented or rescued both disease-related behavioral defects
(mostly) and several brain pathologies. Importantly, the
therapeutic effects of the GSK2606414 treatment corre-
lated well with the restoration of both general protein
synthesis and the levels of several synaptic proteins in
the hippocampus [1]. GSK2606414 appears to be ideal
from a ‘translational’ perspective because of its high se-
lectivity and potency for PERK compared with other ki-
nases and has excellent blood–brain barrier penetration.
Given that dysregulation of the PERK/eIF2α pathways
likely represents a common crucial pathological feature
in neurodegenerative diseases [9] and has been well
linked to cognitive impairments (as discussed above), de-
termining whether GSK2606414 is effective in other dis-
ease models such as AD, PD, or HD is important. In
support of this idea, we recently demonstrated that
genetic knockdown of PERK post-development in the
forebrain of AD model mice was able to prevent AD-
associated synaptic plasticity failure and memory impair-
ments [10]. Furthermore, using a different small-molecule
PERK inhibitor, we have observed that β-amyloid-induced
hippocampal long-term potentiation failure is reversed by
PERK inhibition (unpublished data).
On the other hand, it is important to be aware of the ca-
veats in proposing PERK inhibitors as a potential therapy
for neurodegenerative diseases. First, excessive repression
of PERK, as a kinase involved in a generic cellular stress-
response pathway, could hamper the ability of neurons to
respond to cellular stress and could disrupt normal regu-
lation of protein synthesis, thereby causing synaptic dys-
function. For example, it was shown that brain-specific
knockdown of PERK in mice resulted in dramatic impair-
ments in behavioral flexibility in multiple cognitive tasks
[11]. Therefore, fine-tuning the dose and duration of treat-
ment with any PERK inhibitor will be critical to achieve
the desired outcomes: re-establishing the capability oftriggering de novo protein synthesis in response to learn-
ing while retaining the cellular stress-response component
of the UPR-PERK-eIF2α pathway. Second, in addition to
its critical role in the brain, PERK activity is essential for
skeletal system development and normal pancreatic func-
tion [12]. Indeed, Wolcott-Rallison syndrome in humans,
which is characterized by early-onset diabetes mellitus,
has been linked to mutations in the EIF2AK3 gene in
humans [13]. In agreement, it is not surprising that Mor-
eno and colleagues reported that GSK2606414 caused
weight loss and hyperglycemia in mice. So that these un-
desired and harmful side effects can be avoided, it would
be ideal to modify the inhibitors so that they would act
predominantly in the brain without effects in peripheral
tissues and organs. Third and last, the study by Moreno
and colleagues also found that memory loss in prion dis-
ease model mice as evaluated by performance in the ob-
ject recognition task was not restored if the PERK
inhibitor treatment was started at a relatively late stage,
after the onset of neuronal loss and the appearance of
clinical symptoms of the disease. These findings reinforce
the importance of early intervention for neurodegenera-
tive disease therapies, which would require the develop-
ment of appropriate biomarkers to detect these diseases
before the manifestation of clinical symptoms [14].
Conclusions
Drug development for neurodegenerative diseases such
as AD has been unsuccessful [15], and thus identifica-
tion of alternative therapeutic targets based on novel
mechanistic studies is urgently needed. Dysregulation of
the UPR/PERK/eIF2α signaling pathway now has been
identified as a potential contributing factor to patho-
physiology associated with neurodegenerative diseases,
and PERK has emerged as a potential novel therapeutic
target. The findings of Moreno and colleagues support
the aforementioned ideas by demonstrating the amelior-
ating effects of a novel small-molecule PERK inhibitor
on disease phenotypes displayed by prion disease model
mice. It will be exciting to determine whether PERK in-
hibitors can also alleviate the pathophysiology observed
in other mouse models of neurodegenerative diseases
and for PERK inhibitors to be tested in clinical settings
as therapies for humans with neurodegenerative disease.
At the same time, we should be cautious about applying
this therapeutic strategy and be mindful not to disrupt
the cellular and synaptic homeostasis by excessive re-
pression of PERK-eIF2α signaling.
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